The study will help us to understand if TX000045 improves blood flow from the lungs back to the heart, improves filling of participants’ hearts with blood, improves participants’ ability to exercise and to see if there are any side effects.
Research Objectives
Status
Recruitment
Total participants required
Study location
Study type
Patient group
About this clinical trial
Tectonic Therapeutic is developing the investigational (experimental) drug TX000045 as a potential new treatment for patients with high lung blood pressure due to heart failure. TX000045 works in a similar way to a hormone called “Relaxin”. Hormones are natural substances in the body that act as messengers in your blood to control various functions. Relaxin relaxes blood vessels and brings down blood pressure. It is hoped that the study drug TX000045 might be able to help people with lung blood pressure problems by reducing the blood pressure in their lungs and making it easier for their hearts to pump blood.
Eligibility
- Diagnosis of pulmonary hypertension (secondary to heart failure or cardiovascular disease)
- Aged 18-80 years
- BMI 18- 45 kg/m2
- Stable cardiovascular medical therapy
Lead investigator
- Dr John Feenstra
Clinical trial coordinators
- Bronwen Field
- Chris Henderson
- Marie-Louise Oegema
Technical title
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)
Contact us
If you would like more information about this clinical trial, please complete the contact form below.